ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) GF Score : 74/100 (As of Apr. 29, 2024)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals GF Score?

ACADIA Pharmaceuticals has the GF Score of 74, which implies that the company is Likely to have average performance.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 3/10
3. Growth Rank : 10/10
4. GF Value Rank : 4/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes ACADIA Pharmaceuticals is Likely to have average performance.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of ACADIA Pharmaceuticals's GF Score

For the Biotechnology subindustry, ACADIA Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACADIA Pharmaceuticals's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's GF Score falls into.

ACADIA Pharmaceuticals (NAS:ACAD) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

ACADIA Pharmaceuticals GF Score Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (NAS:ACAD) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

DR6:Germany DR6:Germany

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia-pharm.com

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Executives

Austin D. Kim	officer: EVP & General Counsel	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Brendan Teehan	officer: EVP, COO, Head of Commercial	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Stephen Davis	director, officer: PRESIDENT AND CEO	ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James Kihara	officer: Principal Accounting Officer	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark C. Schneyer	officer: Chief Financial Officer	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Douglas J Williamson	officer: Executive VP, Research & Dev	AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Srdjan R. Stankovic	officer: EVP	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Adora Ndu	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Elena Ridloff	officer: EVP and CFO	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Michael J. Yang	officer: EVP AND CCO	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Eric Alejandro Miller	officer: Controller & PAO	C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130